Technology

Developing Natural Killer Cell Assassins

The Company’s NK Cell therapy platform is built on over 20 years of peer-reviewed research utilizing patented proprietary methods to activate the innate immune system as “living drugs” for disease. The therapy has shown it is safe, and promising signs of efficacy in multiple clinical trials of various cancers.

Clinical Trials

AP44 NK Cell Therapy: Phase I Clinical Trial Completed

Phase I Completed:                                     n=12

Indication:

  • Therapy-refractory Metastatic Colorectal cancer
  • Non-Small Cell Lung Cancer

Treatment:

  • AP44 NK Cell Therapy, following Radiochemotherapy

Clinical responses:

  • Safety and tolerability
  • Promising signs of efficacy
Take-Away: AP44 NK cell therapy is a safe therapy

AP44 NK Cell: Randomized Phase II Clinical Trial Completed

Phase II Completed:                                     N=14

Indication:

  • Advanced (Stage IIIb) Non-Small Cell Lung Cancer (NSCLC)

Treatment:

  • Treated Group: AP44 NK Cell Therapy, following Radiochemotherapy
  • Control Group: Radiochemotherapy Standard of Care

Clinical responses:

  • Treated Group: Clinical Benefit over 70% Treated Group (5 patients of total of 7 patients) including one Complete Response.
  • Control Group: Response Arm 28% (2 patients of total of 7 patients)
Take-away: AP44 NK cell therapy showed promising signs of clinical benefits in patients in inoperable advanced NSCLC after radio-chemotherapy.

CDx-dx: Companion Diagnostic

Our Companion Diagnostic is a patented monoclonal antibody that is being developed to detect probability of cancer by measuring the membrane form of Hsp70, Normal tissues do not measure to be Hsp70 membrane-positive.